Robert Molpus
Psychiatry · Longwood, FLNPI 1255306734
Payments from drug & device makers
Across 1,715 payments — averaging $3231.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$875K
- AbbVie$835K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$715K
- Indivior Inc.$568K
- Takeda Pharmaceuticals U.S.A., Inc.$490K
- Teva Pharmaceuticals USA, Inc.$401K
- plus $1.7M from 20 others
Across 24 payments — averaging $408.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$6K
- Neos Therapeutics, LP$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$925
- Teva Pharmaceuticals USA, Inc.$764
- Eli Lilly$560
What the payments were for
- Travel & lodging$87074%
- Food & beverage$31226%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 33 | $874,987 |
| AbbVie(2 entities) | 206 | $835,196 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $715,430 |
| Indivior Inc. | 157 | $568,427 |
| Takeda Pharmaceuticals U.S.A., Inc. | 354 | $490,439 |
| Teva Pharmaceuticals USA, Inc. | 97 | $400,861 |
| Boehringer Ingelheim | 26 | $305,764 |
| Biohaven Pharmaceuticals, Inc. | 34 | $234,440 |
| Supernus Pharmaceuticals, Inc. | 48 | $199,474 |
| Corium, LLC | 18 | $137,303 |
| Dermavant Sciences, Inc. | 471 | $121,513 |
| Shire North American Group Inc | 31 | $118,593 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $117,837 |
| Sage Therapeutics, LLC | 4 | $101,731 |
| Sumitomo Pharma America, Inc. | 43 | $83,136 |
| Acadia Pharmaceuticals Inc | 16 | $65,295 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $62,964 |
| Sunovion Pharmaceuticals Inc. | 53 | $33,457 |
| Pfizer | 9 | $20,710 |
| Neurocrine Biosciences, Inc. | 12 | $16,128 |
| GRT US Holding, Inc. | 4 | $13,718 |
| Swing Therapeutics, Inc. | 6 | $12,638 |
| Boehringer Ingelheim International GmbH | 36 | $7,807 |
| Eli Lilly | 2 | $2,339 |
| Amneal Pharmaceuticals LLC | 1 | $1,000 |
| Jazz Pharmaceuticals Inc. | 1 | $413 |
How this compares
$5,541,601 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Longwood
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.